Commonwealth Equity Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.57M | Sell |
15,270
-86
| -0.6% | -$12.8K | ﹤0.01% | 1893 |
|
|
2026
Q1 | $2.02M | Buy |
15,356
+855
| +6% | +$113K | ﹤0.01% | 2005 |
|
|
2025
Q4 | $2.06M | Buy |
14,501
+178
| +1% | +$25.8K | ﹤0.01% | 1964 |
|
|
2025
Q3 | $2.01M | Buy |
14,323
+222
| +2% | +$30.1K | ﹤0.01% | 1979 |
|
|
2025
Q2 | $1.77M | Buy |
14,101
+390
| +3% | +$44.7K | ﹤0.01% | 2082 |
|
|
2025
Q1 | $1.52M | Sell |
13,711
-245
| -2% | -$31K | ﹤0.01% | 2131 |
|
|
2024
Q4 | $1.91M | Sell |
13,956
-1,320
| -9% | -$163K | ﹤0.01% | 1904 |
|
|
2024
Q3 | $1.76M | Buy |
15,276
+360
| +2% | +$49.4K | ﹤0.01% | 1897 |
|
|
2024
Q2 | $2.05M | Buy |
14,916
+975
| +7% | +$134K | ﹤0.01% | 1770 |
|
|
2024
Q1 | $1.92M | Buy |
13,941
+84
| +0.6% | +$11.5K | ﹤0.01% | 1816 |
|
|
2023
Q4 | $1.83M | Sell |
13,857
-150
| -1% | -$17.3K | ﹤0.01% | 1758 |
|
|
2023
Q3 | $1.58M | Sell |
14,007
-1,097
| -7% | -$116K | ﹤0.01% | 1769 |
|
|
2023
Q2 | $1.42M | Sell |
15,104
-234
| -2% | -$22.9K | ﹤0.01% | 1858 |
|
|
2023
Q1 | $1.55M | Buy |
15,338
+200
| +1% | +$20.8K | ﹤0.01% | 1726 |
|
|
2022
Q4 | $1.81M | Buy |
15,138
+440
| +3% | +$51.5K | ﹤0.01% | 1563 |
|
|
2022
Q3 | $1.56M | Sell |
14,698
-1,809
| -11% | -$184K | ﹤0.01% | 1593 |
|
|
2022
Q2 | $1.61M | Sell |
16,507
-2,138
| -11% | -$197K | ﹤0.01% | 1564 |
|
|
2022
Q1 | $1.75M | Buy |
18,645
+182
| +1% | +$15.4K | ﹤0.01% | 1589 |
|
|
2021
Q4 | $1.57M | Sell |
18,463
-342
| -2% | -$31.5K | ﹤0.01% | 1659 |
|
|
2021
Q3 | $1.8M | Sell |
18,805
-1,375
| -7% | -$130K | ﹤0.01% | 1494 |
|
|
2021
Q2 | $1.96M | Buy |
20,180
+537
| +3% | +$51.5K | 0.01% | 1426 |
|
|
2021
Q1 | $1.91M | Sell |
19,643
-1,221
| -6% | -$128K | 0.01% | 1348 |
|
|
2020
Q4 | $2M | Sell |
20,864
-3,278
| -14% | -$317K | 0.01% | 1231 |
|
|
2020
Q3 | $2.32M | Buy |
24,142
+217
| +0.9% | +$25.1K | 0.01% | 1011 |
|
|
2020
Q2 | $2.92M | Buy |
23,925
+705
| +3% | +$77.9K | 0.01% | 831 |
|
|
2020
Q1 | $2.01M | Buy |
23,220
+265
| +1% | +$25.9K | 0.01% | 896 |
|
|
2019
Q4 | $2.47M | Buy |
22,955
+8,721
| +61% | +$913K | 0.01% | 924 |
|
|
2019
Q3 | $1.28M | Sell |
14,234
-232
| -2% | -$21.7K | 0.01% | 1209 |
|
|
2019
Q2 | $1.22M | Sell |
14,466
-576
| -4% | -$47.3K | 0.01% | 1231 |
|
|
2019
Q1 | $1.32M | Buy |
15,042
+4,665
| +45% | +$390K | 0.01% | 1126 |
|
|
2018
Q4 | $741K | Sell |
10,377
-681
| -6% | -$65.2K | ﹤0.01% | 1382 |
|
|
2018
Q3 | $1.36M | Buy |
11,058
+8,989
| +434% | +$1.02M | 0.01% | 1130 |
|
|
2018
Q2 | $203K | Buy |
+2,069
| New | +$185K | ﹤0.01% | 2453 |
|
Other funds holding NBIX
Commonwealth Equity Services's NBIX Position: Q2 2026 in Review
Commonwealth Equity Services reduced its Neurocrine Biosciences (NBIX) stake by 0.56% in Q2 2026, selling an estimated $12.8K and leaving 15,270 shares worth $2.57M. The position accounts for ﹤0.01% of the portfolio, ranked #1893.
Commonwealth Equity Services first reported a position in NBIX in Q2 2018 and has held it in 33 quarters since. The position peaked at $2.92M in Q2 2020. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Commonwealth Equity Services held 15,270 shares of Neurocrine Biosciences worth $2.57M as of Q2 2026.
- Commonwealth Equity Services sold 86 Neurocrine Biosciences shares in Q2 2026, an estimated $12.8K.
- Neurocrine Biosciences made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #1893 holding.
- Commonwealth Equity Services first reported a position in Neurocrine Biosciences in Q2 2018 and has held it in 33 quarters since.
- Commonwealth Equity Services's Neurocrine Biosciences position peaked at $2.92M in Q2 2020.
- 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.